Anika Interest Expense from 2010 to 2024

ANIK Stock  USD 17.72  0.52  3.02%   
Anika Therapeutics Interest Expense yearly trend continues to be quite stable with very little volatility. The value of Interest Expense is projected to decrease to about 1.3 M. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. View All Fundamentals
 
Interest Expense  
First Reported
1993-03-31
Previous Quarter
1.2 M
Current Value
592 K
Quarterly Volatility
380.3 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.9 M, Interest Expense of 1.3 M or Selling General Administrative of 103.5 M, as well as many indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0 or PTB Ratio of 1.73. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Latest Anika Therapeutics' Interest Expense Growth Pattern

Below is the plot of the Interest Expense of Anika Therapeutics over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Anika Therapeutics' Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Interest Expense10 Years Trend
Very volatile
   Interest Expense   
       Timeline  

Anika Interest Expense Regression Statistics

Arithmetic Mean1,391,064
Geometric Mean0.00
Coefficient Of Variation161.59
Mean Deviation1,511,133
Median446,500
Standard Deviation2,247,758
Sample Variance5.1T
Range7.9M
R-Value0.11
Mean Square Error5.4T
R-Squared0.01
Significance0.70
Slope53,849
Total Sum of Squares70.7T

Anika Interest Expense History

20241.3 M
20232.3 M
2022654 K
2021188 K
2020302 K
20197.9 M
20181.5 M

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as Interest Expense, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Interest Expense2.3 M1.3 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.64)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.